<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00737971</url>
  </required_header>
  <id_info>
    <org_study_id>108/08</org_study_id>
    <nct_id>NCT00737971</nct_id>
  </id_info>
  <brief_title>Efficacy Study of Triamcinolone and Bevacizumab Intravitreal for Treatment of Diabetic Macular Edema</brief_title>
  <acronym>ATEMD</acronym>
  <official_title>A Randomized, Parallel Group, Masked Clinical Study to Evaluate the Efficacy of Triamcinolone and Bevacizumab Through Intravitreal Injection With Individual or Simultaneous Drugs to Treatment of Diabetic Macular Edema</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rubens Belfort Jr.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Federal University of S達o Paulo</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Triamcinolone and Bevacizumab Intravitreal for Treatment of Diabetic Macular Edema
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Efficacy Study of Triamcinolone and Bevacizumab Intravitreal for Treatment of Diabetic
      Macular Edema
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2008</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Measurement of visual acuity (E Snellen)</measure>
    <time_frame>monthly</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tonometry</measure>
    <time_frame>monthly</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of retinal thickness by OCT</measure>
    <time_frame>monthly</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">142</enrollment>
  <condition>Diabetic Macular Edema</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Avastin intravitreal injection D0, Week 4, Week 8</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Triamcinolone intravitreal injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Avastin + Triamcinolone intravitreal injection simultaneously</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab intravitreal</intervention_name>
    <description>Bevacizumab intravitreal 0.05 ml/1.25 mg - administered on D0, Week 4, Week 8</description>
    <arm_group_label>A</arm_group_label>
    <other_name>Avastin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Triamcinolone</intervention_name>
    <description>Intravitreal 0.1 ml/4 mg, D0, Week 4 and Week 8</description>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Triamcinolone + Bevacizumab</intervention_name>
    <description>Intravitreal triamcinolone 0.1 ml/4 mg + bevacizumab 0.05 ml/1.25 mg simultaneously on D0, week 4, Week 8</description>
    <arm_group_label>C</arm_group_label>
    <other_name>triamcinolone + avastin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 years of age at least

          -  Diagnosis of diabetes mellitus (type 1 or type 2. any one of the following will be
             considered to be sufficient evidence that diabetes is present:

               -  current regular use of insulin for the treatment of diabetes

               -  current regular use of oral hypoglycemic agents for the treatment of diabetes

               -  diabetes as defined by american Diabetes Association (ADA)

               -  symptoms of diabetes (polyuria, polydipsia, and unexplained weight loss) or
                  eighth-hour fasting plasma glucose &gt; 126 mg/dl

          -  Diabetic macular edema clinically observable associated with diabetic retinopathy:

               -  without prior foveal treatment with laser therapy

               -  if photocoagulation or peripherical or macular laser, at least 3 months

               -  absence of macular ischemia by fluorescein angiography on baseline visit

          -  BCVA score between 20 letters (20/400 ETDRS)e 70 letters (20/40 ETDRS) in the study
             eye measured by the ETDRS method at qualification/baseline visit

          -  Retinal thickness &gt; 275um by OCT

          -  One eye per patient will be chosen for the study. In case of both eye eligible, it
             will be chosen an eye to be treated with study medication and another eye treated with
             laser

          -  Taught hyaloid syndrome

        Exclusion Criteria:

          -  Uncontrolled systemic disease

          -  Initiation of medical therapy for diabetes or a change from oral hypoglycemic agents
             to insulin therapy within 4 months prior to the qualification visit

          -  Renal failure requiring hemodialysis or peritoneal dialysis within 6 months prior to
             the qualification visit

          -  Any ocular condition in the study eye that in the opinion of the investigator would
             prevent a 2 lines improvement of visual acuity (e.g. severe macular ischemia)

          -  Presence of branch retinal vein occlusion, central retinal vein occlusion, uveitis,
             pseudophakic cystoid edema or any other condition in the study eye which could be
             contributing to macular edema

          -  Presence of an epiretinal membrane in the study eye

          -  History of IOP elevation in response to steroid treatment in either eye

          -  History of glaucoma or optic nerve head change consistent with glaucoma damage

          -  Ocular hypertension requiring more than 1 anti-glaucoma medication to maintain IOP &lt;
             11mmhg at qualification visit

          -  Presence of anterior chamber intraocular lens in the study eye

          -  Active optic disc or retinal neovascularization in the study eye at qualification
             visit

          -  Active or history of choroidal neovascularization in the study eye
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rubens Belfort Jr, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Federal University of S達o Paulo / Dept. of OPhthalmology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Federal University of Sao Paulo - Dept. of Ophthalmology / Vision Institute</name>
      <address>
        <city>S達o Paulo</city>
        <zip>04040-002</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 19, 2008</study_first_submitted>
  <study_first_submitted_qc>August 19, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 20, 2008</study_first_posted>
  <last_update_submitted>April 29, 2016</last_update_submitted>
  <last_update_submitted_qc>April 29, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 3, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Federal University of S達o Paulo</investigator_affiliation>
    <investigator_full_name>Rubens Belfort Jr.</investigator_full_name>
    <investigator_title>Head Professor</investigator_title>
  </responsible_party>
  <keyword>avastin</keyword>
  <keyword>bevacizumab</keyword>
  <keyword>triamcinolone</keyword>
  <keyword>diabetic macular edema</keyword>
  <keyword>macular edema</keyword>
  <keyword>intravitreal injection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Edema</mesh_term>
    <mesh_term>Macular Edema</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Triamcinolone hexacetonide</mesh_term>
    <mesh_term>Triamcinolone</mesh_term>
    <mesh_term>Triamcinolone Acetonide</mesh_term>
    <mesh_term>Triamcinolone diacetate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>data presented in several congresses: ARVO 2010-- poster ARVO 2011, WOC BERLIN 2010, WOC ABU DABHI 2012 (partial data) CBO 2014 (final data)</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

